Latest News

In part 1 of a 2-part Q&A, John Berdahl, MD, discusses the widening global cataract surgical gap and examines emerging evidence linking cataract extraction to a reduced risk of dementia.

Guidance includes building on existing science, reducing redundant testing, and accelerating treatments for rare and life-threatening diseases

NYU Langone’s Jordan Mandell, MD, and Ariana Levin, MD, sit down with UCLA’s Anne Coleman, MD, to discuss her recent study on cardiovascular risk scores and their association with glaucoma, AMD, and other ocular diseases.

The company confirmed it does not plan to submit a New Drug Application (NDA) to the US Food and Drug Administration (FDA)

The topical synthetic peptide receives orphan drug and fast track status and enters phase 2 as a first-in-class treatment for a rare degenerative corneal disease.

Samsung Bioepis launched Opuviz, an aflibercept biosimilar, in Europe for wet AMD, DME, retinal vein occlusion, and myopic CNV.

The study, led by researchers at Keio University School of Medicine, measured near add power in 6258 patients aged 40 to 79.

Andrew G. Lee, MD, and Drew Carey, MD, discuss recurrence of papilledema after discontinuation of GLP-1 receptor agonists and the implications for monitoring patients with idiopathic intracranial hypertension.

Two cases illustrate how recognizing and treating Demodex can change surgical outcomes and resolve chronic dry eye disease.

The resubmission follows a successful appeal by the company with the Office of New Drugs (OND).

Knowing pregnancy-related risks enhances patient safety.

Therini Bio begins a phase 1b DME trial of THN391, an intravitreal antibody targeting fibrin-driven retinal inflammation.

The next-generation FSYX ocular pressure adjusting pump adds wireless connectivity to transmit patient usage data to prescribing practices.